Osthole Induces Hepatic Stellate Cell Ferroptosis to Alleviate Liver Fibrosis by Inhibiting the Y‐Box Binding Protein 1‐Wnt/β‐Catenin Axis Through Downregulating Myocyte Enhancer Factor 2A
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Ming Tong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan Pro…. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Ferroptosis, Liver Cirrhosis, Coumarins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Mechanism of Osthole-Mediated Ubiquitination Degradation of NUAK1, Activation of Iron Death and Inhibition of Liver Fibrosis, Hunan Natural Science Foundation, Hunan Science and Technology Department, 2025-2027, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Liver fibrosis is pathologically associated with ferroptosis. Osthole ( OST ) has good therapeutic effects on liver fibrosis. Our study sought to investigate the pharmacological effects of OST on ferroptosis in hepatic stellate cells ( HSCs ) during the development of liver fibrosis and define the mechanisms involved. The in vivo model of liver fibrosis was established by CCl 4 treatment. MTT and EDU assays were used to assess cell viability and proliferation, respectively. The interaction between myocyte enhancer factor 2A ( MEF2A ) and Y‐box binding protein 1 ( YBX1 ) was analyzed by dual luciferase reporter and chromatin immunoprecipitation ( ChIP ) assays. OST treatment alleviated CCl 4 ‐induced liver fibrosis in mice by activating ferroptosis. OST induced ferroptosis in HSCs and inhibited the activation of HSCs in vitro, while these effects of OST were reversed by MEF2A overexpression or YBX1 overexpression. Mechanistically, MEF2A activated the Wnt/β‐catenin signaling by transcriptionally facilitating YBX1 expression. As expected, the inactivation of Wnt/β‐catenin signaling or YBX1 knockdown could reverse the regulatory effect of MEF2A upregulation on the activation of HSCs and ferroptosis in OST ‐treated HSCs . OST mitigated liver fibrosis by inducing ferroptosis in HSCs and repressing the activation of HSCs through inhibiting the MEF2A / YBX1 /Wnt/β‐catenin axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan Province, China.
- Department of Geriatrics, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan Province, China.
Förderung
- Mechanism of Osthole-Mediated Ubiquitination Degradation of NUAK1, Activation of Iron Death and Inhibition of Liver Fibrosis
- Hunan Natural Science Foundation, Hunan Science and Technology Department, 2025-2027
- Natural Science Foundation of Hunan Province
Zitieren
APA
Tong, M., Liu, M., Chen, L., Lin, Y. H., & Zheng, Q. (2025). Osthole Induces Hepatic Stellate Cell Ferroptosis to Alleviate Liver Fibrosis by Inhibiting the Y‐Box Binding Protein 1‐Wnt/β‐Catenin Axis Through Downregulating Myocyte Enhancer Factor 2A. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70113
Vancouver
Tong M, Liu M, Chen L, Lin YH, Zheng Q. Osthole Induces Hepatic Stellate Cell Ferroptosis to Alleviate Liver Fibrosis by Inhibiting the Y‐Box Binding Protein 1‐Wnt/β‐Catenin Axis Through Downregulating Myocyte Enhancer Factor 2A. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70113
BibTeX
@article{Tong2025,
author = {Tong, Ming and Liu, Meng and Chen, Liang and Lin, Yi-He and Zheng, Qing},
title = {Osthole Induces Hepatic Stellate Cell Ferroptosis to Alleviate Liver Fibrosis by Inhibiting the Y‐Box Binding Protein 1‐Wnt/β‐Catenin Axis Through Downregulating Myocyte Enhancer Factor 2A},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70113}
}
EUVIMED